## DGX: Quest Diagnostics Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.42 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($168.71)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. RSI Alert: Quest Diagnostics Now Oversold**
- Source: Nasdaq | 20260102T170809 | Somewhat-Bullish | Relevance: 100%
- Quest Diagnostics, Inc. (Symbol: DGX) has entered oversold territory, with its Relative Strength Index (RSI) hitting 29.5. This low RSI, combined with a 1.84% annual dividend yield, could signal an attractive entry point for investors. The article suggests that the recent heavy selling might be exhausting itself, making it a good time for dividend investors to research the company further.

**2. Boston Trust Walden Corp Sells 53,026 Shares of Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251231T094747 | Neutral | Relevance: 100%
- Boston Trust Walden Corp significantly reduced its stake in Quest Diagnostics Incorporated, selling 53,026 shares during the third quarter, resulting in holdings worth $5.64 million. Despite this reduction, other institutional investors have recently increased their positions in the medical research company. Quest Diagnostics reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend of $0.80 per share.

**3. NeoGenomics appoints diagnostics veteran Jack Kenny to board By Investing.com**
- Source: Investing.com Nigeria | 20251231T060927 | Neutral | Relevance: 60%
- NeoGenomics, Inc. has appointed John P. "Jack" Kenny, a diagnostics industry veteran with over 30 years of experience, to its Board of Directors. Kenny's appointment fills the vacancy left by Dr. Alison Hannah and is expected to support the company's growth in next-generation cancer testing. This news follows strong third-quarter earnings for 2025 and a favorable patent dispute ruling for NeoGenomics.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($1.18M) |
| Sells | 5 ($3.52M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.8% (+0.1%)
- Blackrock Inc.: 9.0% (-3.0%)
- JPMORGAN CHASE & CO: 7.8% (+99.3%)
- Price (T.Rowe) Assoc: 6.3% (-2.6%)
- State Street Corpora: 4.7% (+0.8%)

### Key Risks

1. Insider selling cluster: $3.5M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.42 suggests fair value with growth premium. Forward P/E 16.7x stretched relative to 6% growth. Insider selling cluster ($3.5M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.4B |
| Beta | 0.62 |
| 52W Range | $148.70 - $197.55 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.42 |
| Forward P/E | 16.7 |
| Current P/E | 17.7 |
| YoY Growth | 5.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -3.4% to -2.0% (+1.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 6.0pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.1%) - potential reversal signal. Underperforming sector by 3.7pp, stock-specific weakness. Below SMA200 (0.98x), long-term trend not supportive. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.02% (CS: 20) | Weak |
| RSI_14 | 34.1 | Neutral |
| MACD Histogram | -0.40 | Bearish |
| vs SMA20 | 0.974x | Below |
| vs SMA50 | 0.958x | Below |
| vs SMA200 | 0.980x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $173.79
- **Stop Loss:** $168.71 (2.9% risk)
- **Target:** $183.95 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 283
- **Position Value:** $49,182.57
- **Portfolio %:** 49.18%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-01-27 (Est: $2.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.60 | +3.9% |
| 2025Q2 | $2.57 | $2.62 | +1.9% |
| 2025Q1 | $2.15 | $2.21 | +2.8% |
| 2024Q4 | $2.18 | $2.23 | +2.1% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*